Global Hemostasis and Tissue Sealing Agents
Global Hemostasis and Tissue Sealing Agents

Hemostasis and Tissue Sealing Agents Comprehensive Study by Type (Topical Hemostats (Mechanical Hemostats, Active Hemostats, Flowable Hemostats, Fibrin Sealants, and Topical Thrombin Products), Adhesive and Tissue Sealing Agents (Natural Tissue Sealants, Synthetic Tissue Sealants, Adhesion Barrier Products)), Application (Minimally Invasive Surgery, General Surgery, Others) Players and Region - Global Market Outlook to 2026

Hemostasis and Tissue Sealing Agents Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Feb 2021 Edition 236 Pages 223 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Hemostasis and Tissue Sealing Agents Market?

The hemostasis and tissue sealing agents are used to restrict bleeding caused due to injuries or during surgeries. During surgeries, it is important to stop the bleeding of the patient, to avoid further damage or death due to blood loss, hemostasis, and tissue sealing agents are used. These agents are available in the market in the form of gels, powder, sponges, patches, and other formulations. The FDA has approved numerous hemostatic products that would further project the growth of the global hemostasis and tissue sealing agents market in the forecast period.

The market study is being classified by Type (Topical Hemostats (Mechanical Hemostats, Active Hemostats, Flowable Hemostats, Fibrin Sealants, and Topical Thrombin Products) and Adhesive and Tissue Sealing Agents (Natural Tissue Sealants, Synthetic Tissue Sealants, Adhesion Barrier Products)), by Application (Minimally Invasive Surgery, General Surgery and Others) and major geographies with country level break-up.

Advanced Medical Solutions Group plc (United Kingdom), Baxter International Inc. (United States), Cohera Medical, Inc. (Slovenia), CryoLife, Inc. (United States), C.R. Bard, Inc. (United States), Johnson & Johnson (United States), Integra LifeSciences Corporation (United States), Pfizer, Inc. (United States), B Braun Medical Inc. (Germany), Medtronic (United States), CSL Behring (United States) and CryoLife (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Zimmer Biomet (United States), Ferrosan Medical Devices (Denmark), Smith & Nephew (United Kingdom), Z-Medica (United States) and Marine Polymer (United States).

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Hemostasis and Tissue Sealing Agents market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Hemostasis and Tissue Sealing Agents market by Type, Application and Region.

On the basis of geography, the market of Hemostasis and Tissue Sealing Agents has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Growth in Geriatric Population and Prevalence of Chronic Conditions
  • Increase in Cases of Wound and Routine Injuries

Market Trend
  • Rising Number of Surgeries such as Hernia Fixation, Orthopedic Surgery, and Others

Restraints
  • Stringent Regulatory Scenario Regarding Approval of Hemostasis and Tissue Sealing Agents

Opportunities
  • Increasing Advancement in Technology and Rising Incidences of Cardiovascular Surgeries which Result in High Demand for Hemostat Devices

Challenges
  • Increasing uses of Off Label Hemostat Products





Key Target Audience
Hemostasis and Tissue Sealing Agents Manufacturers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Topical Hemostats (Mechanical Hemostats, Active Hemostats, Flowable Hemostats, Fibrin Sealants, and Topical Thrombin Products)
  • Adhesive and Tissue Sealing Agents (Natural Tissue Sealants, Synthetic Tissue Sealants, Adhesion Barrier Products)
By Application
  • Minimally Invasive Surgery
  • General Surgery
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growth in Geriatric Population and Prevalence of Chronic Conditions
      • 3.2.2. Increase in Cases of Wound and Routine Injuries
    • 3.3. Market Challenges
      • 3.3.1. Increasing uses of Off Label Hemostat Products
    • 3.4. Market Trends
      • 3.4.1. Rising Number of Surgeries such as Hernia Fixation, Orthopedic Surgery, and Others
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hemostasis and Tissue Sealing Agents, by Type, Application and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Hemostasis and Tissue Sealing Agents (Value)
      • 5.2.1. Global Hemostasis and Tissue Sealing Agents by: Type (Value)
        • 5.2.1.1. Topical Hemostats (Mechanical Hemostats, Active Hemostats, Flowable Hemostats, Fibrin Sealants, and Topical Thrombin Products)
        • 5.2.1.2. Adhesive and Tissue Sealing Agents (Natural Tissue Sealants, Synthetic Tissue Sealants, Adhesion Barrier Products)
      • 5.2.2. Global Hemostasis and Tissue Sealing Agents by: Application (Value)
        • 5.2.2.1. Minimally Invasive Surgery
        • 5.2.2.2. General Surgery
        • 5.2.2.3. Others
      • 5.2.3. Global Hemostasis and Tissue Sealing Agents Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Hemostasis and Tissue Sealing Agents: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Advanced Medical Solutions Group plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Baxter International Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Cohera Medical, Inc. (Slovenia)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. CryoLife, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. C.R. Bard, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson & Johnson (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Integra LifeSciences Corporation (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. B Braun Medical Inc. (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Medtronic (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. CSL Behring (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. CryoLife (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Hemostasis and Tissue Sealing Agents Sale, by Type, Application and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Hemostasis and Tissue Sealing Agents (Value)
      • 7.2.1. Global Hemostasis and Tissue Sealing Agents by: Type (Value)
        • 7.2.1.1. Topical Hemostats (Mechanical Hemostats, Active Hemostats, Flowable Hemostats, Fibrin Sealants, and Topical Thrombin Products)
        • 7.2.1.2. Adhesive and Tissue Sealing Agents (Natural Tissue Sealants, Synthetic Tissue Sealants, Adhesion Barrier Products)
      • 7.2.2. Global Hemostasis and Tissue Sealing Agents by: Application (Value)
        • 7.2.2.1. Minimally Invasive Surgery
        • 7.2.2.2. General Surgery
        • 7.2.2.3. Others
      • 7.2.3. Global Hemostasis and Tissue Sealing Agents Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hemostasis and Tissue Sealing Agents: by Type(USD Million)
  • Table 2. Hemostasis and Tissue Sealing Agents Topical Hemostats (Mechanical Hemostats, Active Hemostats, Flowable Hemostats, Fibrin Sealants, and Topical Thrombin Products) , by Region USD Million (2015-2020)
  • Table 3. Hemostasis and Tissue Sealing Agents Adhesive and Tissue Sealing Agents (Natural Tissue Sealants, Synthetic Tissue Sealants, Adhesion Barrier Products) , by Region USD Million (2015-2020)
  • Table 4. Hemostasis and Tissue Sealing Agents: by Application(USD Million)
  • Table 5. Hemostasis and Tissue Sealing Agents Minimally Invasive Surgery , by Region USD Million (2015-2020)
  • Table 6. Hemostasis and Tissue Sealing Agents General Surgery , by Region USD Million (2015-2020)
  • Table 7. Hemostasis and Tissue Sealing Agents Others , by Region USD Million (2015-2020)
  • Table 8. South America Hemostasis and Tissue Sealing Agents, by Country USD Million (2015-2020)
  • Table 9. South America Hemostasis and Tissue Sealing Agents, by Type USD Million (2015-2020)
  • Table 10. South America Hemostasis and Tissue Sealing Agents, by Application USD Million (2015-2020)
  • Table 11. Brazil Hemostasis and Tissue Sealing Agents, by Type USD Million (2015-2020)
  • Table 12. Brazil Hemostasis and Tissue Sealing Agents, by Application USD Million (2015-2020)
  • Table 13. Argentina Hemostasis and Tissue Sealing Agents, by Type USD Million (2015-2020)
  • Table 14. Argentina Hemostasis and Tissue Sealing Agents, by Application USD Million (2015-2020)
  • Table 15. Rest of South America Hemostasis and Tissue Sealing Agents, by Type USD Million (2015-2020)
  • Table 16. Rest of South America Hemostasis and Tissue Sealing Agents, by Application USD Million (2015-2020)
  • Table 17. Asia Pacific Hemostasis and Tissue Sealing Agents, by Country USD Million (2015-2020)
  • Table 18. Asia Pacific Hemostasis and Tissue Sealing Agents, by Type USD Million (2015-2020)
  • Table 19. Asia Pacific Hemostasis and Tissue Sealing Agents, by Application USD Million (2015-2020)
  • Table 20. China Hemostasis and Tissue Sealing Agents, by Type USD Million (2015-2020)
  • Table 21. China Hemostasis and Tissue Sealing Agents, by Application USD Million (2015-2020)
  • Table 22. Japan Hemostasis and Tissue Sealing Agents, by Type USD Million (2015-2020)
  • Table 23. Japan Hemostasis and Tissue Sealing Agents, by Application USD Million (2015-2020)
  • Table 24. India Hemostasis and Tissue Sealing Agents, by Type USD Million (2015-2020)
  • Table 25. India Hemostasis and Tissue Sealing Agents, by Application USD Million (2015-2020)
  • Table 26. South Korea Hemostasis and Tissue Sealing Agents, by Type USD Million (2015-2020)
  • Table 27. South Korea Hemostasis and Tissue Sealing Agents, by Application USD Million (2015-2020)
  • Table 28. Taiwan Hemostasis and Tissue Sealing Agents, by Type USD Million (2015-2020)
  • Table 29. Taiwan Hemostasis and Tissue Sealing Agents, by Application USD Million (2015-2020)
  • Table 30. Australia Hemostasis and Tissue Sealing Agents, by Type USD Million (2015-2020)
  • Table 31. Australia Hemostasis and Tissue Sealing Agents, by Application USD Million (2015-2020)
  • Table 32. Rest of Asia-Pacific Hemostasis and Tissue Sealing Agents, by Type USD Million (2015-2020)
  • Table 33. Rest of Asia-Pacific Hemostasis and Tissue Sealing Agents, by Application USD Million (2015-2020)
  • Table 34. Europe Hemostasis and Tissue Sealing Agents, by Country USD Million (2015-2020)
  • Table 35. Europe Hemostasis and Tissue Sealing Agents, by Type USD Million (2015-2020)
  • Table 36. Europe Hemostasis and Tissue Sealing Agents, by Application USD Million (2015-2020)
  • Table 37. Germany Hemostasis and Tissue Sealing Agents, by Type USD Million (2015-2020)
  • Table 38. Germany Hemostasis and Tissue Sealing Agents, by Application USD Million (2015-2020)
  • Table 39. France Hemostasis and Tissue Sealing Agents, by Type USD Million (2015-2020)
  • Table 40. France Hemostasis and Tissue Sealing Agents, by Application USD Million (2015-2020)
  • Table 41. Italy Hemostasis and Tissue Sealing Agents, by Type USD Million (2015-2020)
  • Table 42. Italy Hemostasis and Tissue Sealing Agents, by Application USD Million (2015-2020)
  • Table 43. United Kingdom Hemostasis and Tissue Sealing Agents, by Type USD Million (2015-2020)
  • Table 44. United Kingdom Hemostasis and Tissue Sealing Agents, by Application USD Million (2015-2020)
  • Table 45. Netherlands Hemostasis and Tissue Sealing Agents, by Type USD Million (2015-2020)
  • Table 46. Netherlands Hemostasis and Tissue Sealing Agents, by Application USD Million (2015-2020)
  • Table 47. Rest of Europe Hemostasis and Tissue Sealing Agents, by Type USD Million (2015-2020)
  • Table 48. Rest of Europe Hemostasis and Tissue Sealing Agents, by Application USD Million (2015-2020)
  • Table 49. MEA Hemostasis and Tissue Sealing Agents, by Country USD Million (2015-2020)
  • Table 50. MEA Hemostasis and Tissue Sealing Agents, by Type USD Million (2015-2020)
  • Table 51. MEA Hemostasis and Tissue Sealing Agents, by Application USD Million (2015-2020)
  • Table 52. Middle East Hemostasis and Tissue Sealing Agents, by Type USD Million (2015-2020)
  • Table 53. Middle East Hemostasis and Tissue Sealing Agents, by Application USD Million (2015-2020)
  • Table 54. Africa Hemostasis and Tissue Sealing Agents, by Type USD Million (2015-2020)
  • Table 55. Africa Hemostasis and Tissue Sealing Agents, by Application USD Million (2015-2020)
  • Table 56. North America Hemostasis and Tissue Sealing Agents, by Country USD Million (2015-2020)
  • Table 57. North America Hemostasis and Tissue Sealing Agents, by Type USD Million (2015-2020)
  • Table 58. North America Hemostasis and Tissue Sealing Agents, by Application USD Million (2015-2020)
  • Table 59. United States Hemostasis and Tissue Sealing Agents, by Type USD Million (2015-2020)
  • Table 60. United States Hemostasis and Tissue Sealing Agents, by Application USD Million (2015-2020)
  • Table 61. Canada Hemostasis and Tissue Sealing Agents, by Type USD Million (2015-2020)
  • Table 62. Canada Hemostasis and Tissue Sealing Agents, by Application USD Million (2015-2020)
  • Table 63. Mexico Hemostasis and Tissue Sealing Agents, by Type USD Million (2015-2020)
  • Table 64. Mexico Hemostasis and Tissue Sealing Agents, by Application USD Million (2015-2020)
  • Table 65. Company Basic Information, Sales Area and Its Competitors
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Hemostasis and Tissue Sealing Agents: by Type(USD Million)
  • Table 78. Hemostasis and Tissue Sealing Agents Topical Hemostats (Mechanical Hemostats, Active Hemostats, Flowable Hemostats, Fibrin Sealants, and Topical Thrombin Products) , by Region USD Million (2021-2026)
  • Table 79. Hemostasis and Tissue Sealing Agents Adhesive and Tissue Sealing Agents (Natural Tissue Sealants, Synthetic Tissue Sealants, Adhesion Barrier Products) , by Region USD Million (2021-2026)
  • Table 80. Hemostasis and Tissue Sealing Agents: by Application(USD Million)
  • Table 81. Hemostasis and Tissue Sealing Agents Minimally Invasive Surgery , by Region USD Million (2021-2026)
  • Table 82. Hemostasis and Tissue Sealing Agents General Surgery , by Region USD Million (2021-2026)
  • Table 83. Hemostasis and Tissue Sealing Agents Others , by Region USD Million (2021-2026)
  • Table 84. South America Hemostasis and Tissue Sealing Agents, by Country USD Million (2021-2026)
  • Table 85. South America Hemostasis and Tissue Sealing Agents, by Type USD Million (2021-2026)
  • Table 86. South America Hemostasis and Tissue Sealing Agents, by Application USD Million (2021-2026)
  • Table 87. Brazil Hemostasis and Tissue Sealing Agents, by Type USD Million (2021-2026)
  • Table 88. Brazil Hemostasis and Tissue Sealing Agents, by Application USD Million (2021-2026)
  • Table 89. Argentina Hemostasis and Tissue Sealing Agents, by Type USD Million (2021-2026)
  • Table 90. Argentina Hemostasis and Tissue Sealing Agents, by Application USD Million (2021-2026)
  • Table 91. Rest of South America Hemostasis and Tissue Sealing Agents, by Type USD Million (2021-2026)
  • Table 92. Rest of South America Hemostasis and Tissue Sealing Agents, by Application USD Million (2021-2026)
  • Table 93. Asia Pacific Hemostasis and Tissue Sealing Agents, by Country USD Million (2021-2026)
  • Table 94. Asia Pacific Hemostasis and Tissue Sealing Agents, by Type USD Million (2021-2026)
  • Table 95. Asia Pacific Hemostasis and Tissue Sealing Agents, by Application USD Million (2021-2026)
  • Table 96. China Hemostasis and Tissue Sealing Agents, by Type USD Million (2021-2026)
  • Table 97. China Hemostasis and Tissue Sealing Agents, by Application USD Million (2021-2026)
  • Table 98. Japan Hemostasis and Tissue Sealing Agents, by Type USD Million (2021-2026)
  • Table 99. Japan Hemostasis and Tissue Sealing Agents, by Application USD Million (2021-2026)
  • Table 100. India Hemostasis and Tissue Sealing Agents, by Type USD Million (2021-2026)
  • Table 101. India Hemostasis and Tissue Sealing Agents, by Application USD Million (2021-2026)
  • Table 102. South Korea Hemostasis and Tissue Sealing Agents, by Type USD Million (2021-2026)
  • Table 103. South Korea Hemostasis and Tissue Sealing Agents, by Application USD Million (2021-2026)
  • Table 104. Taiwan Hemostasis and Tissue Sealing Agents, by Type USD Million (2021-2026)
  • Table 105. Taiwan Hemostasis and Tissue Sealing Agents, by Application USD Million (2021-2026)
  • Table 106. Australia Hemostasis and Tissue Sealing Agents, by Type USD Million (2021-2026)
  • Table 107. Australia Hemostasis and Tissue Sealing Agents, by Application USD Million (2021-2026)
  • Table 108. Rest of Asia-Pacific Hemostasis and Tissue Sealing Agents, by Type USD Million (2021-2026)
  • Table 109. Rest of Asia-Pacific Hemostasis and Tissue Sealing Agents, by Application USD Million (2021-2026)
  • Table 110. Europe Hemostasis and Tissue Sealing Agents, by Country USD Million (2021-2026)
  • Table 111. Europe Hemostasis and Tissue Sealing Agents, by Type USD Million (2021-2026)
  • Table 112. Europe Hemostasis and Tissue Sealing Agents, by Application USD Million (2021-2026)
  • Table 113. Germany Hemostasis and Tissue Sealing Agents, by Type USD Million (2021-2026)
  • Table 114. Germany Hemostasis and Tissue Sealing Agents, by Application USD Million (2021-2026)
  • Table 115. France Hemostasis and Tissue Sealing Agents, by Type USD Million (2021-2026)
  • Table 116. France Hemostasis and Tissue Sealing Agents, by Application USD Million (2021-2026)
  • Table 117. Italy Hemostasis and Tissue Sealing Agents, by Type USD Million (2021-2026)
  • Table 118. Italy Hemostasis and Tissue Sealing Agents, by Application USD Million (2021-2026)
  • Table 119. United Kingdom Hemostasis and Tissue Sealing Agents, by Type USD Million (2021-2026)
  • Table 120. United Kingdom Hemostasis and Tissue Sealing Agents, by Application USD Million (2021-2026)
  • Table 121. Netherlands Hemostasis and Tissue Sealing Agents, by Type USD Million (2021-2026)
  • Table 122. Netherlands Hemostasis and Tissue Sealing Agents, by Application USD Million (2021-2026)
  • Table 123. Rest of Europe Hemostasis and Tissue Sealing Agents, by Type USD Million (2021-2026)
  • Table 124. Rest of Europe Hemostasis and Tissue Sealing Agents, by Application USD Million (2021-2026)
  • Table 125. MEA Hemostasis and Tissue Sealing Agents, by Country USD Million (2021-2026)
  • Table 126. MEA Hemostasis and Tissue Sealing Agents, by Type USD Million (2021-2026)
  • Table 127. MEA Hemostasis and Tissue Sealing Agents, by Application USD Million (2021-2026)
  • Table 128. Middle East Hemostasis and Tissue Sealing Agents, by Type USD Million (2021-2026)
  • Table 129. Middle East Hemostasis and Tissue Sealing Agents, by Application USD Million (2021-2026)
  • Table 130. Africa Hemostasis and Tissue Sealing Agents, by Type USD Million (2021-2026)
  • Table 131. Africa Hemostasis and Tissue Sealing Agents, by Application USD Million (2021-2026)
  • Table 132. North America Hemostasis and Tissue Sealing Agents, by Country USD Million (2021-2026)
  • Table 133. North America Hemostasis and Tissue Sealing Agents, by Type USD Million (2021-2026)
  • Table 134. North America Hemostasis and Tissue Sealing Agents, by Application USD Million (2021-2026)
  • Table 135. United States Hemostasis and Tissue Sealing Agents, by Type USD Million (2021-2026)
  • Table 136. United States Hemostasis and Tissue Sealing Agents, by Application USD Million (2021-2026)
  • Table 137. Canada Hemostasis and Tissue Sealing Agents, by Type USD Million (2021-2026)
  • Table 138. Canada Hemostasis and Tissue Sealing Agents, by Application USD Million (2021-2026)
  • Table 139. Mexico Hemostasis and Tissue Sealing Agents, by Type USD Million (2021-2026)
  • Table 140. Mexico Hemostasis and Tissue Sealing Agents, by Application USD Million (2021-2026)
  • Table 141. Research Programs/Design for This Report
  • Table 142. Key Data Information from Secondary Sources
  • Table 143. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hemostasis and Tissue Sealing Agents: by Type USD Million (2015-2020)
  • Figure 5. Global Hemostasis and Tissue Sealing Agents: by Application USD Million (2015-2020)
  • Figure 6. South America Hemostasis and Tissue Sealing Agents Share (%), by Country
  • Figure 7. Asia Pacific Hemostasis and Tissue Sealing Agents Share (%), by Country
  • Figure 8. Europe Hemostasis and Tissue Sealing Agents Share (%), by Country
  • Figure 9. MEA Hemostasis and Tissue Sealing Agents Share (%), by Country
  • Figure 10. North America Hemostasis and Tissue Sealing Agents Share (%), by Country
  • Figure 11. Global Hemostasis and Tissue Sealing Agents share by Players 2020 (%)
  • Figure 12. Global Hemostasis and Tissue Sealing Agents share by Players (Top 3) 2020(%)
  • Figure 13. Global Hemostasis and Tissue Sealing Agents share by Players (Top 5) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Advanced Medical Solutions Group plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 16. Advanced Medical Solutions Group plc (United Kingdom) Revenue: by Geography 2020
  • Figure 17. Baxter International Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Baxter International Inc. (United States) Revenue: by Geography 2020
  • Figure 19. Cohera Medical, Inc. (Slovenia) Revenue, Net Income and Gross profit
  • Figure 20. Cohera Medical, Inc. (Slovenia) Revenue: by Geography 2020
  • Figure 21. CryoLife, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. CryoLife, Inc. (United States) Revenue: by Geography 2020
  • Figure 23. C.R. Bard, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. C.R. Bard, Inc. (United States) Revenue: by Geography 2020
  • Figure 25. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 26. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 27. Integra LifeSciences Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 28. Integra LifeSciences Corporation (United States) Revenue: by Geography 2020
  • Figure 29. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer, Inc. (United States) Revenue: by Geography 2020
  • Figure 31. B Braun Medical Inc. (Germany) Revenue, Net Income and Gross profit
  • Figure 32. B Braun Medical Inc. (Germany) Revenue: by Geography 2020
  • Figure 33. Medtronic (United States) Revenue, Net Income and Gross profit
  • Figure 34. Medtronic (United States) Revenue: by Geography 2020
  • Figure 35. CSL Behring (United States) Revenue, Net Income and Gross profit
  • Figure 36. CSL Behring (United States) Revenue: by Geography 2020
  • Figure 37. CryoLife (United States) Revenue, Net Income and Gross profit
  • Figure 38. CryoLife (United States) Revenue: by Geography 2020
  • Figure 39. Global Hemostasis and Tissue Sealing Agents: by Type USD Million (2021-2026)
  • Figure 40. Global Hemostasis and Tissue Sealing Agents: by Application USD Million (2021-2026)
  • Figure 41. South America Hemostasis and Tissue Sealing Agents Share (%), by Country
  • Figure 42. Asia Pacific Hemostasis and Tissue Sealing Agents Share (%), by Country
  • Figure 43. Europe Hemostasis and Tissue Sealing Agents Share (%), by Country
  • Figure 44. MEA Hemostasis and Tissue Sealing Agents Share (%), by Country
  • Figure 45. North America Hemostasis and Tissue Sealing Agents Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Advanced Medical Solutions Group plc (United Kingdom)
  • Baxter International Inc. (United States)
  • Cohera Medical, Inc. (Slovenia)
  • CryoLife, Inc. (United States)
  • C.R. Bard, Inc. (United States)
  • Johnson & Johnson (United States)
  • Integra LifeSciences Corporation (United States)
  • Pfizer, Inc. (United States)
  • B Braun Medical Inc. (Germany)
  • Medtronic (United States)
  • CSL Behring (United States)
  • CryoLife (United States)
Additional players considered in the study are as follows:
Zimmer Biomet (United States) , Ferrosan Medical Devices (Denmark) , Smith & Nephew (United Kingdom) , Z-Medica (United States) , Marine Polymer (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation